[{"address1": "840 Memorial Drive", "city": "Cambridge", "state": "MA", "zip": "02139", "country": "United States", "phone": "617 498 0020", "website": "https://www.mersana.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 123, "companyOfficers": [{"maxAge": 1, "name": "Dr. Martin H. Huber M.D.", "age": 62, "title": "President, CEO & Director", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 780460, "exercisedValue": 0, "unexercisedValue": 9648}, {"maxAge": 1, "name": "Mr. Brian C. DeSchuytner", "age": 45, "title": "Senior VP, CFO & COO", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 567039, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Timothy B. Lowinger Ph.D.", "age": 59, "title": "Senior VP and Chief Science & Technology Officer", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 587528, "exercisedValue": 0, "unexercisedValue": 82056}, {"maxAge": 1, "name": "Ms. Alejandra Veronica Carvajal J.D.", "age": 49, "title": "Senior VP, Secretary & Chief Legal Officer", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 558117, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mohan  Bala Ph.D.", "age": 58, "title": "Senior VP & Chief Development Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 549430, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mikhail  Papisov Ph.D.", "title": "Co-Founder", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ashish  Mandelia", "age": 48, "title": "Chief Accounting Officer", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jason  Fredette", "title": "Senior Vice President of Investor Relations & Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Chuck  Miller", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Marc  Damelin", "title": "Exe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery & Develop.", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 7, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.44, "open": 1.42, "dayLow": 1.34, "dayHigh": 1.48, "regularMarketPreviousClose": 1.44, "regularMarketOpen": 1.42, "regularMarketDayLow": 1.34, "regularMarketDayHigh": 1.48, "beta": 1.465, "forwardPE": -2.0, "volume": 1010460, "regularMarketVolume": 1010460, "averageVolume": 1238204, "averageVolume10days": 897050, "averageDailyVolume10Day": 897050, "bid": 1.41, "ask": 1.44, "bidSize": 400, "askSize": 600, "marketCap": 174198496, "fiftyTwoWeekLow": 1.065, "fiftyTwoWeekHigh": 6.28, "priceToSalesTrailing12Months": 5.818836, "fiftyDayAverage": 1.7571, "twoHundredDayAverage": 2.80765, "currency": "USD", "enterpriseValue": 46843072, "floatShares": 72294861, "sharesOutstanding": 122675000, "sharesShort": 8487549, "sharesShortPriorMonth": 9573255, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0692, "heldPercentInsiders": 0.01355, "heldPercentInstitutions": 0.94641, "shortRatio": 6.16, "shortPercentOfFloat": 0.091000006, "bookValue": 0.069, "priceToBook": 20.57971, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -104774000, "trailingEps": -0.85, "forwardEps": -0.71, "enterpriseToRevenue": 1.565, "enterpriseToEbitda": -0.462, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "MRSN", "underlyingSymbol": "MRSN", "shortName": "Mersana Therapeutics, Inc.", "longName": "Mersana Therapeutics, Inc.", "firstTradeDateEpochUtc": 1498656600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f2bdb9ce-4a35-377e-aaea-f82800954196", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.42, "targetHighPrice": 9.0, "targetLowPrice": 3.0, "targetMeanPrice": 6.5, "targetMedianPrice": 7.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 162742000, "totalCashPerShare": 1.327, "ebitda": -101411000, "totalDebt": 32933000, "quickRatio": 2.642, "currentRatio": 2.717, "totalRevenue": 29937000, "debtToEquity": 390.803, "revenuePerShare": 0.247, "returnOnAssets": -0.26297, "returnOnEquity": -2.1333, "freeCashflow": -66514624, "operatingCashflow": -132555000, "revenueGrowth": -0.785, "grossMargins": -1.93807, "operatingMargins": -11.10118, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]